Upcoming Earnings: Q2 '26
Estimated EPS
-$0.19
Estimated Rev
$0.82M
$MIST Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.20 up 35.48% YoY • Reported revenue of $0.24M • Milestone Pharmaceuticals Inc. expects its existing cash, cash equivalents, and short-term investments of $184.2M as of March 31, 2026, to be sufficient to fund operations for at least the next 12 months.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.19 | -- | -- | N/A |
Q1 '26 | $0.19 | -$0.20 | -205.26% | MISSED |
Q4 '25 | -$0.16 | -$0.16 | 0.12% | BEAT |
Q3 '25 | -$0.16 | -$0.12 | 26.83% | BEAT |
Q2 '25 | -$0.18 | -$0.20 | -12.68% | MISSED |
